Comparison of the Effects of Solifenacin Succinate for the Treatment of Overactive Bladder with Extended Release Tolterodine

Update on tolterodine extended-release for treatment of overactive bladder

Overactive bladder is a prevalent condition which negatively impacts quality of life and puts a significant economical burden on society. First-line therapy often includes pharmacotherapy with antimuscarinic medications, and numerous research studies have demonstrated that tolterodine extended-release (ER) is an efficacious and tolerable formulation of this class of medication. This review prov...

study of cohesive devices in the textbook of english for the students of apsychology by rastegarpour

this study investigates the cohesive devices used in the textbook of english for the students of psychology. the research questions and hypotheses in the present study are based on what frequency and distribution of grammatical and lexical cohesive devices are. then, to answer the questions all grammatical and lexical cohesive devices in reading comprehension passages from 6 units of 21units th...

Use of Tolterodine extended Release in Overactive Bladder

Overactive bladder (OAB) is a common problem whose prevalence increases with advancing age and compromises ­health-related­quality­of­life.­Tolterodine­was­the­first­antimuscarinic­drug­specifically­designed­to­treat­OAB. Through­MEDLINE,­we­reviewed­articles,­standardization­reports­and­meeting­abstracts,­published­between­2001­and­2011,­on­the­efficacy and tolerability of Tolterodine extended...

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function

INTRODUCTION Overactive bladder (OAB) is a common condition, especially in middle aged women, requiring long term therapy with anticholinergics to maintain symptoms relief. The aim of the study was to determine the effect of tolterodine extended release (ER) used for OAB treatment on the sexual function of women. MATERIALS AND METHODS Between August 2010 and August 2014, 220 women with confir...

Solifenacin succinate (VESIcare): overactive bladder therapy.